Beta Bionics Reports 145% Sales Surge + Dexcom Appoints New CCO

Beta Bionics, newly public, saw a 145% increase in Q4 sales, reaching $20.4 million, driven by nearly 4,100 new patient starts and strong pharmacy adoption. The company anticipates the pharmacy channel will contribute over 20% of new patient starts in 2025. Dexcom named Jon Coleman as Chief Commercial Officer. Formerly with Masimo, Coleman now oversees Dexcom’s global commercial organization, including sales and marketing, as the company focuses on restructuring and growth.

Sibionics received CE mark approval for its GS3 continuous glucose monitor (CGM), touted as the world’s thinnest CGM at 2.9mm. The device leverages AI for glucose management and integrates with smartwatches, enhancing accessibility for users.